Protalix Biotherapeutics Company Profile, Contacts & Intelligence

Biotechnology ResearchIl192 employeesAMERIFounded 1994
3 contacts with email or phone data3 with email data1 with phone data
Employees
192
Company source estimate
Reachable Contacts
3
Visible contacts with email or phone data
Contacts With Email
3
3 of 4 visible contacts
Departments
6
Mapped contact coverage

Protalix Biotherapeutics Overview

Protalix (NYSE American, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix’s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α Galactosidase A protein for the treatment of Fabry disease; alidornase alfa or PRX 110, for the treatment of various human respiratory diseases or conditions; PRX 115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX 119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Headquarters
Il
Industry
Biotechnology Research
Founded
1994
Stock Symbol
AMERI
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Phone Number
Available in AeroLeads
Company Email
Available in AeroLeads

Protalix Biotherapeutics Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

3 contacts with contact data
3 with email data and 1 with phone data in the visible sample.
6 departments represented
Visible contacts with email or phone data are mapped to these departments.
15 company-domain emails
Visible contacts using Protalix Biotherapeutics's company email domain.
General
4
IT
4
Healthcare
3
Executive
2
HR
1
Finance
1

Protalix Biotherapeutics People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Protalix Biotherapeutics Workforce Composition

Seniority breakdown across 28 visible profiles.

Individual contributor
12
Manager
6
Director
4
Senior / Lead
4
VP / Head
1
Associate / junior
1

Protalix Biotherapeutics Technology & Talent

Technology-related job titles represented in the visible people data.

Engineering
6
Cloud / infrastructure
1
Data / AI
1

Compare Similar Companies to Protalix Biotherapeutics

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
Novocure Medical Equipment Manufacturing 1.43K View company
Dexcel Pharma Pharmaceutical Manufacturing 520 View company
Pluri Biotechnology Research 254 View company
CytoReason Biotechnology Research 129 View company
Evogene Biotechnology Research 113 View company
MeMed Biotechnology Research 107 View company
Anima Biotech Biotechnology Research 67 View company
BiomX (NYSE: PHGE) Biotechnology Research 64 View company
BioLineRx Biotechnology Research 54 View company
Bonus Biogroup Biotechnology Research 42 View company